Color Duplex-Guided Sclerotherapy for the Treatment of Venous Malformations

Yamaki, Takashi; Nozaki, Motohiro; Sasaki, Kenji

doi:10.1046/j.1524-4725.2000.99248.x

Cited by 102 publications

(76 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Percutaneous sclerotherapy for venous malformations (VMs) has recently been explored as a successful alternative to surgery [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Traditionally, absolute ethanol has been the agent of choice for sclerotherapy [1][2][3][4][5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

“…It is the most effective sclerosant available, but it also results in the most serious complications, including tissue necrosis, peripheral nerve injury, pulmonary embolism and, unpredictably, pulmonary vasospasm, cardiac arrhythmias, and electromechanical disassociation [5]. Some other sclerosants, such as sodium tetradecyl sulfate and ethanolamine oleate (EO), are also used in sclerotherapy [10][11][12][13][14][15][16]. We have used polidocanol as a first-choice sclerosing agent; this medicine is widely used for sclerotherapy of varicose veins in the lower extremities and esophageal varices in Europe and Japan.…”

Section: Introductionmentioning

confidence: 99%

“…The sclerosing effect of polidocanol is more moderate than that of ethanol [17], and so we expected that the possibility of serious complications could be reduced. Furthermore, polidocanol is virtually painless upon injection due to its anesthetic effect; therefore, general anesthesia is not necessary [14,15]. Previous reports concerning sclerotherapy using polidocanol have mainly evaluated the contraction of lesions by sclerotherapy [14,15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Polidocanol sclerotherapy for painful venous malformations: evaluation of safety and efficacy in pain relief

et al. 2009

View full text Add to dashboard Cite

The aim of this study was to retrospectively evaluate the safety and efficacy of polidocanol sclerotherapy in pain relief for painful venous malformations (VMs). Thirty-one patients with painful VMs underwent polidocanol sclerotherapy. Pain intensity was assessed with an 11-point verbal numerical rating scale. Sclerotherapy was technically successful in 58 (98.3%) of 59 sessions. Twenty-six (89.7%) out of 29 patients experienced an improvement in pain after sclerotherapy at follow-up, a mean of 46 months after treatment. The mean pain score improved from 6.6 + or - 2.5 before treatment to 2.4 + or - 2.9 after treatment (P <.001). The factors that significantly influenced the therapeutic effect were size of lesion (P = .008), margin of lesion (P = .006), and stasis of sclerosant (P = .032). Adverse events included hypotension and bradycardia during the procedure. No major complication occurred. Polidocanol sclerotherapy is safe and most efficacious in providing pain relief for patients with small VMs (equal to or less than 10 cm in diameter), VMs with a well-defined margin, and VMs with good stasis of sclerosant during sclerotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Polidocanol sclerotherapy for painful venous malformations: evaluation of safety and efficacy in pain relief

et al. 2009

View full text Add to dashboard Cite

show abstract

“…One percent polidocanol (hydroxypolyaethoxydodecan; Aethoxysklerol, Kreussler Pharma, Wiesbaden, Germany) has been safely used for the sclerosis of gastroesophageal varices, 1 endoscopic injection of intestinal vascular malformations, 2 cutaneous hemangiomas, 3 and ectatic veins. 4, 5 We present…”

mentioning

confidence: 99%

Sonographically guided percutaneous sclerosis using 1% polidocanol in the treatment of vascular malformations

Jain

Bandhu

Sawhney

et al. 2002

J of Clinical Ultrasound

View full text Add to dashboard Cite

show abstract

“…It has been faced with problems including dispersion of drug into surrounding tissue with significantly reduced therapeutic effect, or invasion of important tissues adjacent to the lesion such as nerves, salivary glands or vessels, which can lead to serious complications. Ultrasound guidance was first used by Yamaki (32)with VMs in the cervical-facial region by intralesional injection of absolute alcohol, and he researched this method in detail with reported advantages like prevention of intra-arterial injections (34,35).…”

Section: Discussionmentioning

confidence: 99%

Ultrasound-guided Intralesional Bleomycin Injection (IBI) for Treatment of Cutaneous Hemangiomas and Vascular Malformations

Memon

Malik

Anjum

et al. 2016

JGR

View full text Add to dashboard Cite

Purpose: To report the therapeutic outcome of ultrasound-guided intralesional injection of bleomycin in the treatment of cutaneous hemangiomas and vascular malformations. Material & Methods:The medical records of patients with cutaneous hemangiomas and vascular malformations treated with the intralesional injection of bleomycin under ultrasound guidance between August 2009 and June 2013 at the Indus Hospital, Karachi were reviewed retrospectively using a computerized medical record information management system. Data were extracted using a pre-coded performa that included patient demographics, type and location of lesion, number of treatments, presenting/pre-and post-treatment clinical symptoms (pain, swelling, heaviness, size, discoloration), ultrasound appearance and vascularity, and post-treatment side effects. The dose range of bleomycin was 0.5-1.0 mg/kg, but not exceeding 15 mg in a single session. A maximum of four treatments were given in any given patient except for one, who presented with recurrence after a year of complete resolution. Therapeutic outcome was determined using review of ultrasound images and recorded clinical assessment. Treatment response was categorized as: (i) complete resolution [more than 90% reduction]; (ii) substantial reduction [more than 50% reduction]; (iii) mild reduction [25% reduction]; or, (iv) no improvement [<10% reduction].Results: A total of 30 patients (16 female, 14 male), ranging in age from 8 months to 48 years (mean age 10.2 years), were treated from 2009 to 2013. There were 23 hemangiomas. Seven were vascular malformations, of which five were lymphatic malformations and two were venous malformations. Twenty-eight lesions were located in the head and neck region, and two were peripheral. In 24 of the 30 patients (76%), treatment had been completed. In six patients (21%) treatment was ongoing at the time of this report. Seventeen of the 23 hemangiomas (74%) were completely resolved clinically and on ultrasound, five (22%) showed substantial improvement and one (4%) showed mild improvement. In five of the seven vascular malformations (71%) lymphatic malformations resolved completely, and two (29%) venous malformations showed substantial improvement. Of the 13 patients presenting with discoloration, there was complete resolution in one (7.7%), marked reduction in 11 (84.6%) and mild reduction in one (7.7%). Of seven patients presenting with pain, there was complete resolution in two (28.6%), marked reduction in two (28.6%), mild reduction in two (28.6%), and no improvement in one (14.3%). There were no pulmonary complications. Conclusion:Ultrasound-guided intralesional injection of bleomycin is an option to consider for the treatment of certain types of cutaneous hemangiomas and vascular malformations. Prospective studies should be undertaken to understand the various factors contributing to therapeutic success. Ultrasound-guided Intralesional Bleomycin Injection (IBI) for Treatment of Cutaneous Hemangiomas and Vascular Malformations

show abstract

Color Duplex-Guided Sclerotherapy for the Treatment of Venous Malformations

Abstract: Color duplex-guided sclerotherapy was effective in 82% of the patients. This procedure prevents intra-arterial injection accidents. Although patients with venous malformations showed greater coagulability, no serious thrombotic sequelae were found.

Cited by 102 publications

References 15 publications

Polidocanol sclerotherapy for painful venous malformations: evaluation of safety and efficacy in pain relief

Polidocanol sclerotherapy for painful venous malformations: evaluation of safety and efficacy in pain relief

Sonographically guided percutaneous sclerosis using 1% polidocanol in the treatment of vascular malformations

Ultrasound-guided Intralesional Bleomycin Injection (IBI) for Treatment of Cutaneous Hemangiomas and Vascular Malformations

Contact Info

Product

Resources

About